< > Celltrion's Truxima sold in 18 European countries
Go Search Go Contents Go to bottom site map

Celltrion's Truxima sold in 18 European countries

2018/06/11 13:59

Article View Option

SEOUL, June 11 (Yonhap) -- An affiliate of South Korean biopharmaceutical firm Celltrion Inc. said Monday that the biosimilar drug Truxima is now available in 18 European countries.

Celltrion Healthcare, which handles Celltrion's overseas business, said Truxima, a reference to Roche's Mabthera, also known as Rituxan, is now available in the European countries after its launch one year ago.

After Truxima began selling in Britain following approval from a European regulator, the drug expanded to the 18 nations, including Germany, France and Italy.

"Truxima logged market shares of 58 percent and 43 percent in the Netherlands and the Britain, respectively, on the back of plentiful clinical data," said a company source, who declined to be named.

In February 2017, the European Medicines Agency (EMA) accepted Celltrion's application to sell the antibody biosimilar, which is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin's lymphoma, a type of leukemia.

The drug is sold in the European countries at a discount to the current list price of Rituxan, the company said.

Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire.

khj@yna.co.kr

(END)

angloinfo.com